EOM Pharmaceuticals Holdings, Inc. (IMUC)
| Market Cap | 18.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.13M |
| Shares Out | 116.05M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,200 |
| Average Volume | 2,725 |
| Open | 0.160 |
| Previous Close | 0.160 |
| Day's Range | 0.120 - 0.160 |
| 52-Week Range | 0.072 - 0.397 |
| Beta | 0.91 |
| RSI | 40.83 |
| Earnings Date | n/a |
About IMUC
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for th... [Read more]
Financial Performance
Financial StatementsNews
EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613
MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613.
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil
Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, ...
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement
MONTVALE, N.J. and LOS ANGELES, Dec. 2, 2021 /PRNewswire/ -- EOM Pharmaceuticals, Inc. ("EOM"), a privately held, clinical-stage pharmaceutical company, and ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market
LOS ANGELES, June 28, 2021 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under ...